Xiao‐Li Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiao‐Li Zhang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Yue Zhang
Department of Physiology and Pathophysiology School of Basic Medical Sciences Capital Medical University Beijing China
3 shared publicationsCai‐Feng Zhang
Department of Physiology and Pathophysiology School of Basic Medical Sciences Capital Medical University Beijing China
2 shared publications- Jin Song
Beijing Hospital of Traditional Chinese Medicine Capital Medical University Beijing China
2 shared publications - Jin-Xia Zhu
Capital Medical University
2 shared publications Dong-Bo Lian
Capital Medical University
1 shared publicationJin Song
Beijing Hospital of Traditional Chinese Medicine Capital Medical University Beijing China
1 shared publication
Latest Publications
- Open Access
- 18 June 2026
- Published by Wiley in Gut Medicine
- Vol. 2 (2) , 65-75
Low‐Concentration Dopamine Potentiates Gastric Motility Through Activation of Dopamine D 5 Receptor on Enteric Cholinergic Neurons
Background: Dopamine (DA) exerts complex concentration‐dependent effects on gastrointestinal motility. Although its inhibitory action through D2‐like receptors is well‐established, the mechanisms underlying its excitatory effects remain elusive. This study investigates the facilitatory effect of low‐concentration DA on gastric corpus motility and identifies the specific receptor and pathway involved. Methods: Gastric motility recording, enzyme‐linked immunosorbent assay (ELISA), double‐labeled immunofluorescence, western blotting, M 2 /M 3 knockout mice, and D 5 R transgenic mice were used in this study. Results: In isolated rat gastric strips, low‐dose DA (10–100 nM) enhanced spontaneous contractions, an effect mimicked by the D1‐like receptor agonist SKF38393 but not by the D2‐like agonist quinpirole. Immunofluorescence revealed that both D 1 R and D 5 R are co‐expressed with cholinergic neurons in the myenteric plexus. The prokinetic effects of DA and SKF38393 were abolished by tetrodotoxin or atropine, indicating neural and cholinergic dependence. Critically, using humanized D 5 R transgenic mice, gain‐of‐function (D 5 S390G ) and loss‐of‐function (D 5 F173L ) mutants, we established D 5 R as indispensable for the excitatory response: D 5 S390G mice showed enhanced contractility to DA and SKF38393, whereas D 5 F173L mice exhibited no response. Furthermore, in M 2 /M 3 muscarinic receptor knockout mice, DA and SKF38393 failed to enhance contractions, confirming the dependence on acetylcholine‐mediated smooth muscle activation. Conclusion: These results identify a novel neurogenic pathway in which low‐concentration DA activates neuronal D 5 R on cholinergic enteric neurons, leading to acetylcholine release and M 2 /M 3 receptor‐mediated contraction of gastric smooth muscle. Our findings establish D 5 R as a critical mediator of dopamine‐induced gastric excitation in ex vivo preparations. Although the present study does not include in vivo experiments, these mechanistic insights suggest that D 5 R may represent a potential therapeutic target for gastroparesis and related motility disorders, warranting further validation in in vivo models.
- 18 June 2026
- Published by Wiley in Gut Medicine
- Vol. 2 (2) , 65-75
Open AccessLow‐Concentration Dopamine Potentiates Gastric Motility Through Activation of Dopamine D 5 Receptor on Enteric Cholinergic Neurons
Background: Dopamine (DA) exerts complex concentration‐dependent effects on gastrointestinal motility. Although its inhibitory action through D2‐like receptors is well‐established, the mechanisms underlying its excitatory effects remain elusive. This study investigates the facilitatory effect of low‐concentration DA on gastric corpus motility and identifies the specific receptor and pathway involved. Methods: Gastric motility recording, enzyme‐linked immunosorbent assay (ELISA), double‐labeled immunofluorescence, western blotting, M 2 /M 3 knockout mice, and D 5 R transgenic mice were used in this study. Results: In isolated rat gastric strips, low‐dose DA (10–100 nM) enhanced spontaneous contractions, an effect mimicked by the D1‐like receptor agonist SKF38393 but not by the D2‐like agonist quinpirole. Immunofluorescence revealed that both D 1 R and D 5 R are co‐expressed with cholinergic neurons in the myenteric plexus. The prokinetic effects of DA and SKF38393 were abolished by tetrodotoxin or atropine, indicating neural and cholinergic dependence. Critically, using humanized D 5 R transgenic mice, gain‐of‐function (D 5 S390G ) and loss‐of‐function (D 5 F173L ) mutants, we established D 5 R as indispensable for the excitatory response: D 5 S390G mice showed enhanced contractility to DA and SKF38393, whereas D 5 F173L mice exhibited no response. Furthermore, in M 2 /M 3 muscarinic receptor knockout mice, DA and SKF38393 failed to enhance contractions, confirming the dependence on acetylcholine‐mediated smooth muscle activation. Conclusion: These results identify a novel neurogenic pathway in which low‐concentration DA activates neuronal D 5 R on cholinergic enteric neurons, leading to acetylcholine release and M 2 /M 3 receptor‐mediated contraction of gastric smooth muscle. Our findings establish D 5 R as a critical mediator of dopamine‐induced gastric excitation in ex vivo preparations. Although the present study does not include in vivo experiments, these mechanistic insights suggest that D 5 R may represent a potential therapeutic target for gastroparesis and related motility disorders, warranting further validation in in vivo models.
- 1 May 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (5) , C1409-C1422
Blocking dopamine receptor 2 decreases gastrin levels in H. pylori-infected mice through increasing gastric somatostatin content
We report novel findings that blocking D2Rs, not D1Rs, decreased the number of gastric gastrin-positive cells and gastrin levels in H. pylori-infected mice. Gastric gastrin secretion induced by DA was indirectly mediated via D2Rs, which suppressed SOM release. These results provide an experimental basis for local regulation of gastric gastrin secretion by DA through D2Rs, offering a potential strategy for preventing and treating high gastrin levels in H. pylori infection.
- 1 May 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (5) , C1409-C1422
Blocking dopamine receptor 2 decreases gastrin levels in H. pylori-infected mice through increasing gastric somatostatin content
We report novel findings that blocking D2Rs, not D1Rs, decreased the number of gastric gastrin-positive cells and gastrin levels in H. pylori-infected mice. Gastric gastrin secretion induced by DA was indirectly mediated via D2Rs, which suppressed SOM release. These results provide an experimental basis for local regulation of gastric gastrin secretion by DA through D2Rs, offering a potential strategy for preventing and treating high gastrin levels in H. pylori infection.
- 27 March 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 37 (7) , e70033
Berberine Improves Depression‐Like Behaviors and Gastrointestinal Dysfunction in 6‐Hydroxydopamine‐Induced Parkinson's Disease Rats
Background: Berberine (BBR) enhances the production of levodopa in gut microbes, which is converted to dopamine in the brain of Parkinson's disease (PD). However, limited research has explored the effects of BBR on non‐motor symptoms, such as depression and gastrointestinal (GI) dysfunction in PD.Methods: 6‐hydroxydopamine‐induced (6‐OHDA) PD rats were utilized in this study, and depression‐like behaviors were detected via the sucrose preference test and open field test.Key Results: The 6‐OHDA rats exhibited depression‐like behaviors, delayed GI transit, decreased colonic motility, and increased mucosal permeability. BBR gavage effectively improved depression‐like behaviors, increased dopamine and 5‐HT content in the midbrain and orexin A (OXA) content in the hypothalamus, but decreased corticotropin‐releasing factor (CRF) content in the hypothalamus of 6‐OHDA rats. Moreover, BBR treatment shortened whole GI transit time, enhanced distal colonic motility, and restored colonic mucosal permeability in 6‐OHDA rats. Furthermore, expression of neuronal nitric oxide synthase protein, choline acetyltransferase mRNA levels, intensity of glial fibrillary acidic protein‐positive enteric glial cells (EGCs), glial cell‐derived neurotrophic factor protein, and goblet cell numbers were increased in the distal colon of 6‐OHDA rats after BBR treatment.Conclusions and Inferences: These findings suggested that BBR ameliorated the colonic dysfunction in 6‐OHDA rats and modulated changes in enteric neurotransmitters and EGCs. Moreover, BBR regulated monoamines in the midbrain and OXA and CRF in the hypothalamus, which are associated with depression‐like behaviors in 6‐OHDA rats. This study provides a theoretical and experimental foundation for the potential application of BBR in treating non‐motor symptoms of PD.
- 27 March 2025
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 37 (7) , e70033
Berberine Improves Depression‐Like Behaviors and Gastrointestinal Dysfunction in 6‐Hydroxydopamine‐Induced Parkinson's Disease Rats
Background: Berberine (BBR) enhances the production of levodopa in gut microbes, which is converted to dopamine in the brain of Parkinson's disease (PD). However, limited research has explored the effects of BBR on non‐motor symptoms, such as depression and gastrointestinal (GI) dysfunction in PD.Methods: 6‐hydroxydopamine‐induced (6‐OHDA) PD rats were utilized in this study, and depression‐like behaviors were detected via the sucrose preference test and open field test.Key Results: The 6‐OHDA rats exhibited depression‐like behaviors, delayed GI transit, decreased colonic motility, and increased mucosal permeability. BBR gavage effectively improved depression‐like behaviors, increased dopamine and 5‐HT content in the midbrain and orexin A (OXA) content in the hypothalamus, but decreased corticotropin‐releasing factor (CRF) content in the hypothalamus of 6‐OHDA rats. Moreover, BBR treatment shortened whole GI transit time, enhanced distal colonic motility, and restored colonic mucosal permeability in 6‐OHDA rats. Furthermore, expression of neuronal nitric oxide synthase protein, choline acetyltransferase mRNA levels, intensity of glial fibrillary acidic protein‐positive enteric glial cells (EGCs), glial cell‐derived neurotrophic factor protein, and goblet cell numbers were increased in the distal colon of 6‐OHDA rats after BBR treatment.Conclusions and Inferences: These findings suggested that BBR ameliorated the colonic dysfunction in 6‐OHDA rats and modulated changes in enteric neurotransmitters and EGCs. Moreover, BBR regulated monoamines in the midbrain and OXA and CRF in the hypothalamus, which are associated with depression‐like behaviors in 6‐OHDA rats. This study provides a theoretical and experimental foundation for the potential application of BBR in treating non‐motor symptoms of PD.